BioPharmSignal logoBioPharmSignal

Biotech News

BriaCell and BriaPro to Present Preclinical Anti-Cancer Activity and Immunotherapy Findings at SITC 2026

BriaCell (BCTX)BriaCellCompany update

BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, and its majority-owned subsidiary, BriaPro Therapeutics Corp. (“BriaPro”), today announced four preclinical research presentations at the Society for Immunotherapy of Cancer (SITC) 41 th Anniversary Annual Meeting, taking place November 4-8, 2026, in Phoenix, AZ.

Related news

BCTXBriaCell2026-10-06 11:30 EST

BriaCell and BriaPro to Present Four Posters at SITC 2026 Annual Meeting

BCTXBriaCell2026-10-23 11:30 EST

BriaCell Announces ESMO 2026 Poster Highlighting Circulating Immune Biomarker Associated with Clinical Outcomes in Metastatic Breast Cancer

GERNGeron2026-11-04 14:00 EST

Geron Corporation to Present Data Highlighting Clinical and Biological Activity of RYTELO® (imetelstat) at ASH 2026

ANABAnaptysBio, Inc.2026-10-19 18:18 EST

Jemperli (dostarlimab) Approved in the U.S. as First and Only Immunotherapy for Adults with MSI-H/dMMR Locally Advanced Rectal Cancer

BNTXBioNTech2026-10-13 10:45 EST

BioNTech Provides Update on Phase 2/3 Clinical Trial for mRNA Cancer Immunotherapy Candidate BNT113 in Metastatic HPV16-positive Head and Neck Cancer

BMYBMYBristol-Myers Squibb Company2026-10-25 07:30 EST

BioNTech and Bristol Myers Squibb Report Encouraging Global Phase 2 data for Pumitamig in Advanced NSCLC After Progression on Immunotherapy Plus Chemotherapy

GSKGSK plc2026-10-13 17:42 EST

Jemperli (dostarlimab) approved in US as first and only immunotherapy for adults with MSI-H/dMMR locally advanced rectal cancer

KURAKura Oncology2026-10-07 11:15 EST

Caspian Therapeutics and Kura Oncology to Host Investor Webcast Highlighting Caspian’s Launch and KO-7246 Preclinical Data in Diabetes

NRIXNurix Therapeutics2026-11-05 12:00 EST

Nurix Therapeutics to Present New and Updated Data from Ongoing Phase 1a/1b Trial of Bexobrutideg (NX-5948) in Relapsed/Refractory CLL/SLL at the 68th ASH Annual Meeting and Exposition

KURAKura Oncology2026-11-04 14:02 EST

Kura Oncology and Kyowa Kirin to Present First Ziftomenib-FLT3 Inhibitor Clinical Data at ASH 2026

View all latest news

BriaCell

Cancer Immunotherapy Developer BriaCell Therapeutics develops immunotherapies intended to stimulate coordinated immune responses against cancer. Its programs combine allogeneic tumor-cell platforms with checkpoint inhibitors and other immune-modulating agents. Bria-IMT in Metastatic Breast Cancer Bria-IMT is an off-the-shelf whole-cell...

Recent company news

BCTXBriaCell2026-11-03 14:00 EST

BriaCell and BriaPro to Present Preclinical Anti-Cancer Activity and Immunotherapy Findings at SITC 2026

BCTXBriaCell2026-10-23 11:30 EST

BriaCell Announces ESMO 2026 Poster Highlighting Circulating Immune Biomarker Associated with Clinical Outcomes in Metastatic Breast Cancer

BCTXBriaCell2026-10-06 11:30 EST

BriaCell and BriaPro to Present Four Posters at SITC 2026 Annual Meeting

BCTXBriaCell2026-09-14 11:30 EST

Data Safety Monitoring Board (DSMB) Recommends Continuing BriaCell’s Phase 3 Metastatic Breast Cancer Study

BCTXBriaCell2026-09-08 11:30 EST

BriaCell’s Pivotal Phase 3 Metastatic Breast Cancer Study Expands to Leading Cancer Center

Stock data

Close
3.27 USD
Market cap
23.71M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States